CARFIMIB(Carfilzomib Injection)

Therapeutic class: Proteasome inhibitor

Indication: multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.